338 related articles for article (PubMed ID: 11351295)
1. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance.
Harbottle A; Daly AK; Atherton K; Campbell FC
Int J Cancer; 2001 Jun; 92(6):777-83. PubMed ID: 11351295
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial involvement of multidrug resistance-associated [correction of resistance] protein, DNA topoisomerase II and glutathione/glutathione-S-transferase in nonP-glycoprotein-mediated multidrug resistance in human bladder cancer cells.
Kim WJ; Kakehi Y; Yoshida O
Int J Urol; 1997 Nov; 4(6):583-90. PubMed ID: 9477189
[TBL] [Abstract][Full Text] [Related]
3. Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1.
Diah SK; Smitherman PK; Townsend AJ; Morrow CS
Toxicol Appl Pharmacol; 1999 Jun; 157(2):85-93. PubMed ID: 10366541
[TBL] [Abstract][Full Text] [Related]
4. Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells.
Cnubben NH; Rommens AJ; Oudshoorn MJ; Van Bladeren PJ
Cancer Res; 1998 Oct; 58(20):4616-23. PubMed ID: 9788613
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
Zaja R; Caminada D; Loncar J; Fent K; Smital T
Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
[TBL] [Abstract][Full Text] [Related]
6. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Hatanaka H; Abe Y; Naruke M; Asai S; Miyachi H; Kawakami T; Nagata J; Kamochi J; Kijima H; Yamazaki H; Scanlon KJ; Ueyama Y; Nakamura M
Anticancer Res; 2001; 21(2A):879-85. PubMed ID: 11396179
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1.
Aouali N; Morjani H; Trussardi A; Soma E; Giroux B; Manfait M
Int J Oncol; 2003 Oct; 23(4):1195-201. PubMed ID: 12964004
[TBL] [Abstract][Full Text] [Related]
8. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
Hour TC; Chen J; Huang CY; Guan JY; Lu SH; Hsieh CY; Pu YS
Anticancer Res; 2000; 20(5A):3221-5. PubMed ID: 11062746
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.
Kim HS; Lee TB; Choi CH
Biochem Biophys Res Commun; 2001 Feb; 281(1):109-14. PubMed ID: 11178967
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
11. Glutathione S-transferases in wild-type and doxorubicin-resistant MCF-7 human breast cancer cell lines.
Wang K; Ramji S; Bhathena A; Lee C; Riddick DS
Xenobiotica; 1999 Feb; 29(2):155-70. PubMed ID: 10199592
[TBL] [Abstract][Full Text] [Related]
12. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
Shepard RL; Cao J; Starling JJ; Dantzig AH
Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation.
Wang H; Li X; Chen T; Wang W; Liu Q; Li H; Yi J; Wang J
Oncol Rep; 2013 Feb; 29(2):676-84. PubMed ID: 23229154
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic.
Liu J; Chen H; Miller DS; Saavedra JE; Keefer LK; Johnson DR; Klaassen CD; Waalkes MP
Mol Pharmacol; 2001 Aug; 60(2):302-9. PubMed ID: 11455017
[TBL] [Abstract][Full Text] [Related]
15. Expression of P-glycoprotein and multidrug resistance associated protein in Ehrlich ascites tumor cells after fractionated irradiation.
Nielsen D; Maare C; Eriksen J; Litman T; Skovsgaard T
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1050-7. PubMed ID: 11704330
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.
Utz I; Gekeler V; Ise W; Beck J; Spitaler M; Grunicke H; Hofmann J
Anticancer Res; 1996; 16(1):289-96. PubMed ID: 8615623
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
[TBL] [Abstract][Full Text] [Related]
18. Reversal of P-glycoprotein and multidrug resistance-associated protein 1 mediated multidrug resistance in cancer cells by HZ08 Isomers, tetrataisohydroquinolin derivatives.
Yan F; Jiang Y; Li YM; Zhen X; Cen J; Fang WR
Biol Pharm Bull; 2008 Jun; 31(6):1258-64. PubMed ID: 18520065
[TBL] [Abstract][Full Text] [Related]
19. Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
Kim HS; Min YD; Choi CH
Biochem Biophys Res Commun; 2001 Apr; 283(1):64-71. PubMed ID: 11322768
[TBL] [Abstract][Full Text] [Related]
20. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH
Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
